MARKET

RCUS

RCUS

Arcus Bioscience
NYSE
23.43
-0.44
-1.84%
After Hours: 23.43 0 0.00% 16:10 05/22 EDT
OPEN
23.84
PREV CLOSE
23.87
HIGH
24.34
LOW
23.42
VOLUME
516.53K
TURNOVER
--
52 WEEK HIGH
28.72
52 WEEK LOW
7.91
MARKET CAP
2.95B
P/E (TTM)
-7.3614
1D
5D
1M
3M
1Y
5Y
1D
Arcus Biosciences Coverage Assumed by Truist Securities at Buy
Dow Jones · 5d ago
Arcus Biosciences Price Target Raised to $35.00/Share From $30.00 by Truist Securities
Dow Jones · 5d ago
Truist Securities Assumes Arcus Biosciences at Buy, Raises Price Target to $35
Benzinga · 5d ago
Arcus Biosciences assumed with a Buy at Truist
TipRanks · 5d ago
Weekly Report: what happened at RCUS last week (0511-0515)?
Weekly Report · 5d ago
Arcus Biosciences, Inc. (NYSE:RCUS) Analysts Just Trimmed Their Revenue Forecasts By 21%
Simply Wall St · 05/16 13:59
Arcus Biosciences Is Maintained at Equal-Weight by Morgan Stanley
Dow Jones · 05/11 17:16
Morgan Stanley Maintains Equal-Weight on Arcus Biosciences, Raises Price Target to $22
Benzinga · 05/11 17:06
More
About RCUS
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.

Webull offers Arcus Biosciences Inc stock information, including NYSE: RCUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RCUS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RCUS stock methods without spending real money on the virtual paper trading platform.